中国生物制药得福组合治疗肺鳞癌III期临床试验获阳性结果

DoNews
23 May

美国临床肿瘤学会年会公布,中国生物制药的“得福组合”(贝莫苏拜单抗+安罗替尼)在一线治疗肺鳞癌III期临床试验中取得成功。数据显示,中位无进展生存期达10.12个月,优于同类药物,疾病进展或死亡风险降低36%。这是全球首个对比PD-1联合化疗取得阳性结果的研究,公司已提交新适应症上市申请。免责声明:本文内容由开放的智能模型自动生成,仅供参考。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10